Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2024 financial results will be released ...

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Exelixis (EXEL) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...

JMP Securities maintained a positive stance on Exelixis (NASDAQ:EXEL) stock, reiterating a Market Outperform rating with a ...

Exelixis (EXEL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason Gerberry from ...

Stephens reiterated their equal weight rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research report report ...

A major downgrade, a billion-dollar pipeline gamble, and a patent war--Exelixis investors brace for a wild ride.

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Exelixis (EXEL – Research Report), with a price target of ...

Exelixis Inc (EXEL) stock saw a modest uptick, ending the day at $32.73 which represents a slight increase of $0.35 or 1.08% from the prior close of $32.38. The stock opened at $32.92 and touched a ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of ...

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U ...

Oppenheimer shifts to a neutral stance on Exelixis, questioning differentiation between zanzalintinib and cabozantinib ...